

Supporting Information

Ruthenium-Catalyzed Remote C5-Sulfonation of *N*-Alkyl-8-Aminoquinolines

Xuri Liu,^a Han Zhang,^a Fanzhi Yang*^a and Bo Wang*^b

^a *Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, 5 South Zhongguancun Street, Haidian District, Beijing, 100081, China.*
E-mail: yangfanzhi@bit.edu.cn

^b *School of Chemistry and Chemical Engineering, Key Laboratory of Cluster Science of Ministry of Education, Beijing Institute of Technology, 5 South Zhongguancun Street, Haidian District, Beijing, 100081, China.*
E-mail: bowang@bit.edu.cn


Contents

| | |
|--|-----|
| General Remarks..... | S2 |
| Preparation and Characterization Data for Compounds 1 | S2 |
| Table S1: Optimization of Catalytic Reaction Conditions..... | S5 |
| Preparation and Characterization Data for Compounds 3 | S6 |
| Mechanistic Study..... | S15 |
| Synthesis of Complex 5 | S15 |
| References..... | S17 |
| NMR Spectra | S18 |


General Remarks

All catalytic reactions were carried out in pre-dried glassware under an argon atmosphere. All solvents were purchased from *Energy Chemical*, *J&K Scientific* and used directly without further purification. Substrates **1a** and **1d-h** were synthesized according to previously described procedures.^[1] Other chemicals were obtained from commercial sources and were used without further purification, unless otherwise noted. TLC: Merck TLC Silica gel 60 F₂₅₄, TLC Aluminum plates. Detection under UV light at 254 nm. Chromatography: Separations were carried out on Qingdao silica gel (60, 0.040-0.063 mm). ¹H-NMR spectra were recorded on a 400 MHz Bruker NMR spectrometer in CDCl₃ (all signals are reported in ppm with the internal chloroform signal at 7.26 ppm). ¹³C-NMR spectra were recorded with ¹H-decoupling on a 101 or 176 MHz Bruker spectrometer in CDCl₃ (all signals are reported in ppm with the internal chloroform signal at 77.16 ppm). Infrared Spectroscopy (IR) were measured on a Bruker FT-IR Alpha device. High-resolution mass spectra (HRMS) were measured on a mass spectrometer (ESI-*oa*-TOF). Melting points (M. p.) were measured on a melting point with a thermometer and the reported values were uncorrected.

Preparation and Characterization Data for Compounds 1




General Procedure A: Literature procedure was used for the synthesis of **1**.^[1] Pd(OAc)₂ (12.8 mg, 1.9 mol %) and BINAP (35.5 mg, 1.9 mol %) were preheated at 85 °C for 30 min in 5 mL of toluene. The mixture was added to a 50 mL reaction bomb flask containing bromoquinoline (3.0 mmol), *tert*-butylamine (329.1 mg, 4.5 mmol), and sodium *tert*-butoxide (403.6 mg, 4.2 mmol) in 10 mL of toluene. The resulting reaction mixture was dark purple and heated at 110 °C for 24 h. The solution was then cooled to room temperature in air, diluted with EA, and washed with H₂O and brine. The organic layer was collected, dried over Na₂SO₄. Removal of solvent in vacuo yielded a dark brown oil, which was purified by flashing through a column of silica with (PE/EA: 20/1) as the eluent to yield the corresponding products.




N-(*tert*-butyl)-quinolin-8-amine (**1a**):

The general procedure A was followed using 8-bromoquinoline (624 mg, 3.0 mmol). Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **1a** (388 mg, 70%) as a yellow liquid. ¹H-NMR (400 MHz, CDCl₃) δ 8.70 (d, *J* = 1.6 Hz, 1H), 8.03 (d, *J* = 8.2 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.02 (d, *J* = 8.1 Hz, 1H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.47 (s, 1H), 1.54 (s, 9H). ¹³C-NMR (101 MHz, CDCl₃) δ 146.6, 143.4, 139.0, 136.2, 129.0, 127.6, 121.3, 113.3, 107.2, 50.7, 29.6. IR (neat): 3373, 2974, 1574, 1526, 1381, 1230, 791 cm⁻¹. HR-MS (ESI) *m/z* calcd. for C₁₃H₁₆N₂ ([M+H]⁺) 201.1392, found: 201.1381.




***N*-(*tert*-butyl)-3-methylquinolin-8-amine (1d):**

The general procedure A was followed using 8-bromo-3-methylquinoline (666 mg, 3.0 mmol). Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **1d** (328 mg, 55%) as a yellow liquid. **¹H-NMR** (400 MHz, CDCl₃) δ 8.54 (d, *J* = 2.1 Hz, 1H), 7.80 (s, 1H), 7.32 (dd, *J* = 7.9, 7.9 Hz, 1H), 7.01 – 6.86 (m, 2H), 2.48 (s, 3H), 1.53 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.5, 143.3, 137.4, 135.0, 130.5, 128.8, 127.6, 112.9, 106.6, 50.7, 29.6, 18.7. **IR** (neat): 3373, 2974, 1576, 1521, 1391, 1228, 748 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₄H₁₉N₂ ([M+H]⁺) 215.1548, found: 215.1537.




***N*-(*tert*-butyl)-6-methylquinolin-8-amine (1e):**

The general procedure A was followed using 8-bromo-6-methylquinoline (666 mg, 3.0 mmol). Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **1e** (358 mg, 60%) as a yellow liquid. **¹H-NMR** (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.2, 1.5 Hz, 1H), 7.94 (dd, *J* = 8.2, 1.1 Hz, 1H), 7.31 (dd, *J* = 8.2, 4.2 Hz, 1H), 6.84 (s, 2H), 2.47 (s, 3H), 1.53 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 145.8, 143.0, 137.9, 137.4, 135.5, 129.0, 121.4, 112.6, 109.3, 50.6, 29.6, 22.8. **IR** (neat): 3371, 2925, 2855, 1574, 1528, 1383, 1232, 830 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₄H₁₉N₂ ([M+H]⁺) 215.1548, found: 215.1541.




***N*-(*tert*-butyl)-6-(trifluoromethyl)quinolin-8-amine (1f):**

The general procedure A was followed using 8-bromo-6-(trifluoromethyl)quinoline (828 mg, 3.0 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **1f** (455 mg, 60%) as a yellow solid. **M. p.**: 71–73 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.76 (s, 1H), 8.09 (s, 1H), 7.42 (s, 1H), 6.96 (s, 1H), 6.62 (s, 1H), 1.53 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.4, 143.9, 139.8, 137.2, 129.4 (q, *J*_{C-F} = 31.5 Hz), 127.8, 124.6 (d, *J*_{C-F} = 272.5 Hz), 122.4, 110.4 (q, *J*_{C-F} = 4.7 Hz), 101.6 (d, *J*_{C-F} = 3.2 Hz), 50.9, 29.3. **¹⁹F-NMR** (377 MHz, CDCl₃) δ -63.0 (s). **IR** (neat): 3383, 2965, 2929, 1579, 1523, 1395, 855 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₄H₁₆F₃N₂ ([M+H]⁺) 269.1266, found: 269.1260.




***N*-(*tert*-butyl)-6-fluoroquinolin-8-amine (1g):**

The general procedure A was followed using 8-bromo-6-fluoroquinoline (678 mg, 3.0 mmol). Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **1g** (243 mg, 40%) as a yellow solid. **M. p.:** 60-62 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.60 (dd, *J* = 4.2, 1.5 Hz, 1H), 7.94 (dd, *J* = 8.3, 1.6 Hz, 1H), 7.34 (dd, *J* = 8.1, 4.1 Hz, 1H), 6.68 – 6.55 (m, 3H), 1.53 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 162.2 (d, *J*_{C-F} = 242.5 Hz), 145.5 (d, *J*_{C-F} = 2.6 Hz), 145.1 (d, *J*_{C-F} = 13.9 Hz), 136.4, 135.7 (d, *J*_{C-F} = 6.0 Hz), 129.5 (d, *J*_{C-F} = 13.1 Hz), 122.2, 96.7 (d, *J*_{C-F} = 3-0.9 Hz), 95.7 (d, *J*_{C-F} = 22.8 Hz), 50.8, 29.3. **¹⁹F-NMR** (377 MHz, CDCl₃) δ -110.6 (s). **IR** (neat): 3369, 2971, 2931, 1576, 1521, 1391, 1224, 834 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₃H₁₆FN₂ ([M+H]⁺) 219.1298, found: 219.1288.



***N*-(tert-butyl)-3, 6-dimethylquinolin-8-amine (1h):**

The general procedure A was followed using 8-bromo-3,6-dimethylquinoline (708 mg, 3.0 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **1h** (377 mg, 59%) as a yellow solid. **M. p.:** 49-51 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.46 (d, *J* = 1.9 Hz, 1H), 7.69 (s, 1H), 6.72 (d, *J* = 3.6 Hz, 2H), 6.31 (s, 1H), 2.45 (s, 3H), 2.45 (s, 3H), 1.53 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 147.6, 142.9, 137.4, 136.3, 134.4, 130.6, 128.8, 112.2, 108.7, 50.7, 29.6, 22.8, 18.7. **IR** (neat): 3381, 2965, 1574, 1515, 1383, 1230, 789 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₅H₂₁N₂ ([M+H]⁺) 229.1705, found: 229.1692.

Table S1: Optimization of Catalytic Reaction Conditions.^a

| Entry | Catalyst | Base | Solvent | Yield (%) ^b |
|-----------------|--|------------------------------------|--------------------|---------------------------|
| 1 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | 1,4-dioxane | 73 |
| 2 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | THF | 65 |
| 3 | [RuCl₂(<i>p</i>-cymene)]₂ | K₂CO₃ | DME | 85(82)^c |
| 4 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | toluene | 61 |
| 5 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | DCE | 37 |
| 6 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | CH ₃ CN | 0 |
| 7 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | Na ₂ CO ₃ | DME | 79 |
| 8 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | Cs ₂ CO ₃ | DME | 10 |
| 9 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₃ PO ₄ | DME | 69 |
| 10 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | NaOAc | DME | 42 |
| 11 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | DBU | DME | 0 |
| 12 | [RuCl ₂ (<i>p</i> -cymene)] ₂ | Et ₃ N | DME | 0 |
| 13 ^d | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | DME | 68 |
| 14 ^e | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | DME | 70 |
| 15 ^f | [RuCl ₂ (<i>p</i> -cymene)] ₂ | K ₂ CO ₃ | DME | 60 |
| 16 | — | K ₂ CO ₃ | DME | 0 |
| 17 ^g | RuCl ₂ (PPh ₃) ₃ | K ₂ CO ₃ | DME | 78 |
| 18 ^g | RuCl ₃ ·3H ₂ O | K ₂ CO ₃ | DME | 47 |
| 19 ^g | CuI | K ₂ CO ₃ | DME | 32 |
| 20 ^g | FeCl ₃ | K ₂ CO ₃ | DME | 13 |
| 21 ^g | Pd(OAc) ₂ | K ₂ CO ₃ | DME | trace |


^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.75 mmol), catalyst (5.0 mol%), base (0.50 mmol), solvent (1.0 ml), 120 °C, 16 h, Ar atmosphere. ^b Yield of ¹H-NMR with 1,3,5-trimethoxybenzene as the internal standard.

^c Isolated yield in parentheses. ^d **2a** (0.50 mmol). ^e At 110 °C. ^f At 130 °C. ^g Catalyst (10.0 mol %).

Preparation and Characterization Data for Compounds 3


General Procedure B:

A 15 mL pressure sealed tube was equipped with a magnetic stir bar and charged with **1** (0.25 mmol), **2** (0.75 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (7.7 mg, 5.0 mol %), and K_2CO_3 (69 mg, 0.50 mmol). The tube was degassed three times with argon, followed by the addition of 1.0 mL anhydrous DME. The mixture was allowed to stir at 120°C for 16 h, and then cooled down to room temperature. The reaction solution was diluted with EtOAc and filtered through a short pad of celite. The filtrate was concentrated *in vacuo* and the resulting residue was purified by column chromatography on silica gel to yield the corresponding products **3**.



N-(*tert*-butyl)-5-tosylquinolin-8-amine (**3aa**):


General procedure B was followed using *N*-(*tert*-butyl)-quinolin-8-amine **1a** (50 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3aa** (73 mg, 82%) as a pale yellow solid. **M. p.**: 162-164 °C. **$^1\text{H-NMR}$** (400 MHz, CDCl_3) δ 8.85 (d, $J = 8.6$ Hz, 1H), 8.64 (d, $J = 1.6$ Hz, 1H), 8.30 (d, $J = 8.6$ Hz, 1H), 7.79 (d, $J = 7.7$ Hz, 2H), 7.41 (dd, $J = 8.0, 3.6$ Hz, 1H), 7.22 (d, $J = 7.8$ Hz, 3H), 6.87 (d, $J = 8.6$ Hz, 1H), 2.34 (s, 3H), 1.54 (s, 9H). **$^{13}\text{C-NMR}$** (101 MHz, CDCl_3) δ 148.2, 146.7, 143.2, 140.6, 138.0, 133.2, 133.1, 129.7, 126.9, 125.4, 123.1, 118.5, 103.6, 77.5, 76.8, 51.2, 29.2, 21.6. **IR** (neat): 3357, 3347, 2963, 2927, 2855, 1562, 1379, 1301, 1260, 1195, 814, 683 cm^{-1} . **HR-MS** (ESI) m/z calcd. for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ ($[\text{M}+\text{H}]^+$) 355.1480, found: 355.1475.



N-(*tert*-pentyl)-5-tosylquinolin-8-amine (**3ba**):


General procedure B was followed using *N*-(*tert*-pentyl)-quinolin-8-amine **1b** (53 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ba** (63 mg, 68%) as a pale yellow solid. **M. p.**: 120-122 °C. **$^1\text{H-NMR}$**

(400 MHz, CDCl₃) δ 8.84 (d, J = 7.8 Hz, 1H), 8.64 (d, J = 2.8 Hz, 1H), 8.28 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.41 (dd, J = 8.7, 4.1 Hz, 1H), 7.22 (d, J = 8.1 Hz, 2H), 7.19 (s, 1H), 6.84 (d, J = 8.7 Hz, 1H), 2.34 (s, 3H), 1.89 (q, J = 7.4 Hz, 2H), 1.48 (s, 6H), 0.92 (t, J = 7.5 Hz, 3H). ¹³C-NMR (101 MHz, CDCl₃) δ 148.3, 146.7, 143.2, 140.6, 138.0, 133.3, 133.1, 129.7, 127.0, 125.4, 123.1, 118.4, 103.4, 54.0, 33.2, 27.0, 21.6, 8.6. **IR** (neat): 3347, 2965, 2920, 2849, 1600, 1562, 1381, 1297, 1132, 814, 681 cm⁻¹. **HR-MS** (ESI) m/z calcd. for C₂₁H₂₅N₂O₂S ([M+H]⁺) 369.1637, found: 369.1624.



N-((3s,5s,7s)-adamantan-1-yl)-5-tosylquinolin-8-amine (**3ca**):


General procedure B was followed using *N*-((3s,5s,7s)-adamantan-1-yl)quinolin-8-amine **1c** (69 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol), and [RuCl₂(*p*-cymene)]₂ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ca** (84 mg, 78%) as a pale yellow solid. **M. p.**: 215-217 °C. ¹H-NMR (400 MHz, CDCl₃) δ 8.84 (d, J = 7.8 Hz, 1H), 8.64 (d, J = 2.8 Hz, 1H), 8.28 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.41 (dd, J = 8.7, 4.1 Hz, 1H), 7.22 (d, J = 8.1 Hz, 2H), 7.19 (s, 1H), 6.84 (d, J = 8.7 Hz, 1H), 2.34 (s, 3H), 1.89 (q, J = 7.4 Hz, 2H), 1.48 (s, 6H), 0.92 (t, J = 7.5 Hz, 3H). ¹³C-NMR (101 MHz, CDCl₃) δ 147.9, 146.6, 143.2, 140.6, 138.0, 133.1, 129.7, 126.9, 125.5, 123.0, 118.2, 104.3, 52.0, 41.9, 36.5, 29.7, 21.6. **IR** (neat): 3322, 2916, 2849, 1601, 1532, 1385, 1300, 1138, 810, 679 cm⁻¹. **HR-MS** (ESI) m/z calcd. for C₂₆H₂₉N₂O₂S ([M+H]⁺) 433.1950, found: 433.1935.



N-(*tert*-butyl)-3-methyl-5-tosylquinolin-8-amine (**3da**):


General procedure B was followed using *N*-(*tert*-butyl)-3-methylquinolin-8-amine **1d** (53 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3da** (56 mg, 61%) as a pale yellow solid. **M. p.**: 205-207 °C. ¹H-NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 8.48 (d, J = 1.7 Hz, 1H), 8.26 (d, J = 8.7 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.1 Hz, 2H), 6.82 (d, J = 8.7 Hz, 1H), 2.45 (s, 3H), 2.35 (s, 3H), 1.54 (s, 9H). ¹³C-NMR (101 MHz, CDCl₃) δ 148.1, 147.9, 143.3, 140.6, 135.8, 133.3, 132.9, 132.6, 129.7, 126.9, 125.4, 118.1, 103.6, 51.5, 29.2, 21.6(d, J = 2.1 Hz), 19.2(d, J = 2.2 Hz). **IR** (neat): 3367, 2963, 2920, 2849, 1566, 1379,

1299, 1224, 1138, 816, 687 cm^{-1} . **HR-MS** (ESI) m/z calcd. for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ ($[\text{M}+\text{H}]^+$) 369.1637, found: 369.1624.




***N*-(*tert*-butyl)-6-methyl-5-tosylquinolin-8-amine (3ea):**

General procedure B was followed using *N*-(*tert*-butyl)-6-methylquinolin-8-amine **1e** (53 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ea** (57 mg, 62%) as a pale yellow solid. **M. p.**: 154-156 °C. **¹H-NMR** (400 MHz, CDCl_3) δ 9.34 (dd, $J = 8.9, 1.3$ Hz, 1H), 8.59 (dd, $J = 4.1, 1.4$ Hz, 1H), 7.72 (d, $J = 8.3$ Hz, 2H), 7.41 (dd, $J = 8.9, 4.1$ Hz, 1H), 7.21 (d, $J = 8.0$ Hz, 2H), 6.69 (s, 1H), 2.83 (s, 3H), 2.35 (s, 3H), 1.54 (s, 9H). **¹³C-NMR** (101 MHz, CDCl_3) δ 146.9, 145.6, 144.3, 143.1, 141.9, 136.7, 134.3, 129.7, 127.6, 126.0, 122.9, 116.2, 110.2, 51.3, 29.2, 24.8 (d, $J = 1.6$ Hz), 21.6 (d, $J = 2.0$ Hz). **IR** (neat): 3349, 2976, 2929, 2865, 1532, 1366, 1299, 1222, 1148, 812, 679 cm^{-1} . **HR-MS** (ESI) m/z calcd. for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ ($[\text{M}+\text{H}]^+$) 369.1637, found: 369.1632.




***N*-(*tert*-butyl)-5-tosyl-6-(trifluoromethyl)-quinolin-8-amine (3fa):**

General procedure B was followed using *N*-(*tert*-butyl)-6-(trifluoromethyl)-quinolin-8-amine **1f** (67 mg, 0.25 mmol), 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol), and $[\text{RuCl}_2(p\text{-cymene})]_2$ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3fa** (55 mg, 52%) as a pale yellow solid. **M. p.**: 172-174 °C. **¹H-NMR** (400 MHz, CDCl_3) δ 9.18 (dd, $J = 9.0, 1.4$ Hz, 1H), 8.69 (dd, $J = 4.0, 1.4$ Hz, 1H), 7.78 (d, $J = 8.3$ Hz, 2H), 7.44 (dd, $J = 9.0, 4.0$ Hz, 2H), 7.28 (s, 1H), 7.23 (d, $J = 8.1$ Hz, 2H), 2.36 (s, 3H), 1.58 (s, 9H). **¹³C-NMR** (101 MHz, CDCl_3) δ 148.1, 143.4, 141.7, 137.7, 135.9, 133.1 (d, $J_{\text{C-F}} = 31.5$ Hz), 129.7, 127.5, 126.2, 123.4, 123.4 (d, $J_{\text{C-F}} = 275.7$ Hz), 117.3, 102.9 (d, $J_{\text{C-F}} = 7.9$ Hz), 100.1, 51.6, 29.2, 21.6. **¹⁹F-NMR** (377 MHz, CDCl_3) δ -53.6 (s). **IR** (neat): 3334, 2923, 2851, 1534, 1305, 1220, 1144, 818, 679 cm^{-1} . **HR-MS** (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{22}\text{F}_3\text{N}_2\text{O}_2\text{S}$ ($[\text{M}+\text{H}]^+$) 423.1354, found: 423.1350.




***N*-(*tert*-butyl)-6-fluoro-5-tosylquinolin-8-amine (3ga):**

General procedure B was followed using *N*-(*tert*-butyl)-6-fluoroquinolin-8-amine **1g** (54 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ga** (73 mg, 70%) as a pale yellow solid. **M. p.**: 147-149 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 9.56 (dd, *J* = 8.8, 1.5 Hz, 1H), 8.61 (dd, *J* = 4.1, 1.5 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 2H), 7.52 (dd, *J* = 8.8, 4.1 Hz, 1H), 7.41 (s, 1H), 7.29 – 7.23 (m, 2H), 6.47 (d, *J* = 15.1 Hz, 1H), 2.38 (s, 3H), 1.50 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 162.6 (d, *J*_{C-F} = 255.4 Hz), 149.7 (d, *J*_{C-F} = 16.4 Hz), 145.8 (d, *J*_{C-F} = 1.8 Hz), 143.6 (s), 141.4 (s), 135.2 (s), 133.4 (d, *J*_{C-F} = 6.9 Hz), 129.7 (s), 126.8 (d, *J*_{C-F} = 1.7 Hz), 123.9 (s), 105.6 (d, *J*_{C-F} = 11.9 Hz), 94.8 (d, *J*_{C-F} = 32.3 Hz), 51.4 (s), 29.0 (s), 21.7 (d, *J* = 1.9 Hz). **¹⁹F-NMR** (377 MHz, CDCl₃) δ -95.8 (s). **IR** (neat): 3332, 2980, 2923, 2872, 1572, 1387, 1303, 1222, 1148, 808, 687 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₂₀H₂₂FN₂O₂S ([M+H]⁺) 373.1386, found: 373.1380.




***N*-(*tert*-butyl)-3,6-dimethyl-5-tosylquinolin-8-amine (3ha):**

General procedure B was followed using *N*-(*tert*-butyl)-3,6-dimethylquinolin-8-amine **1h** (57 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ha** (60 mg, 63%) as a pale yellow solid. **M. p.**: 189-191 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 9.10 (s, 1H), 8.42 (d, *J* = 1.7 Hz, 1H), 7.72 (d, *J* = 8.3 Hz, 2H), 7.21 (d, *J* = 8.1 Hz, 2H), 7.12 (s, 1H), 6.62 (s, 1H), 2.80 (s, 3H), 2.44 (s, 3H), 2.35 (s, 3H), 1.53 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 147.5, 147.2, 144.2, 142.9, 142.2, 135.3, 132.8, 132.5, 129.6, 127.4, 126.0, 115.3, 109.2, 51.0, 29.3, 24.8, 21.6, 19.3. **IR** (neat): 3355, 2982, 2963, 2923, 1552, 1362, 1226, 816, 685 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₂₂H₂₇N₂O₂S ([M+H]⁺) 383.1793, found: 383.1794.




***N*-(5-Tosylquinolin-8-yl)-benzamide (3la):**

General procedure B was followed using *N*-(quinolin-8-yl)-benzamide **1l** (62 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3la** (24 mg, 24%) as a yellow solid. **¹H-NMR** (400 MHz, CDCl₃) δ 10.97 (s, 1H), 9.06 (dd, *J* = 17.3, 8.6 Hz, 2H), 8.88 (s, 1H), 8.55 (d, *J* = 8.3 Hz, 1H), 8.07 (d, *J* = 7.6 Hz, 2H), 7.84 (d, *J* = 7.7 Hz, 2H), 7.59 (dq, *J* = 15.1, 7.4 Hz, 4H), 7.27 (d, *J* = 7.7 Hz, 2H), 2.36 (s, 3H). The spectra data are in accordance with those reported in the literature.²




***N*-phenyl-5-tosylquinolin-8-amine (3ma):**

General procedure B was followed using *N*-phenylquinolin-8-amine **1m** (55 mg, 0.25 mmol) and 4-methylbenzene-1-sulfonyl chloride **2a** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ma** (28 mg, 30%) as a pale yellow solid. **M. p.**: 180-182 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.96 (dd, *J* = 8.7, 1.2 Hz, 1H), 8.77 (dd, *J* = 4.8, 3.6 Hz, 2H), 8.35 (d, *J* = 8.5 Hz, 1H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.50 (dd, *J* = 8.7, 4.2 Hz, 1H), 7.47 – 7.37 (m, 4H), 7.35 (d, *J* = 8.6 Hz, 1H), 7.24 (d, *J* = 8.1 Hz, 2H), 7.19 (dd, *J* = 7.0 Hz, 7.0 Hz, 1H), 2.35 (s, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ 147.6, 146.3, 143.6, 140.2, 139.7, 137.8, 133.3, 133.0, 129.8, 129.8, 127.1, 125.5, 124.7, 123.5, 122.4, 122.3, 104.2, 21.6. **IR** (neat): 3322, 2923, 2857, 1562, 1517, 1377, 1301, 1146, 820, 683 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₂₂H₁₉N₂O₂S ([M+H]⁺) 375.1167, found: 375.1163.




N-(*tert*-butyl)-5-(phenylsulfonyl)-quinolin-8-amine (**3ab**):

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol) and benzenesulfonyl chloride **2b** (132 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ab** (57 mg, 67%) as a pale yellow solid. **M. p.**: 167-169 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.86 (d, *J* = 8.7 Hz, 1H), 8.68 – 8.62 (m, 1H), 8.32 (d, *J* = 8.6 Hz, 1H), 7.91 (d, *J* = 7.4 Hz, 2H), 7.50 – 7.38 (m, 4H), 6.88 (d, *J* = 8.6 Hz, 1H), 1.55 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.2, 146.6, 143.5, 137.9, 133.5, 133.3, 132.5, 129.1, 126.9, 125.5, 123.1, 118.1, 103.8, 51.4, 29.1. **IR** (neat): 3339, 2974, 2965, 2925, 2851, 1562, 1381, 1301, 1218, 1197, 812, 687 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₉H₂₁N₂O₂S ([M+H]⁺) 341.1324, found: 341.1322.



N-(*tert*-butyl)-5-(*m*-tolylsulfonyl)-quinolin-8-amine (**3ac**):


General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol) and 3-methylbenzene-1-sulfonyl chloride **2c** (143 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ac** (66 mg, 75%) as a pale yellow solid. **M. p.**: 146-148 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.86 (d, *J* = 8.6 Hz, 1H), 8.65 (s, 1H), 8.31 (d, *J* = 8.6 Hz, 1H), 7.70 (s, 2H), 7.46 – 7.39 (m, 1H), 7.35 – 7.27 (m, 2H), 6.89 (d, *J* = 8.6 Hz, 1H), 2.35 (s, 3H), 1.55 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.1, 146.6, 143.4, 139.4, 137.9, 133.4, 129.0, 127.2, 125.6, 124.0, 123.1, 118.4, 103.9, 51.4, 29.2, 21.5. **IR** (neat): 3339, 2974, 2918, 2869, 1562, 1381, 1297, 1220, 1197, 810, 702 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₂₀H₂₃N₂O₂S ([M+H]⁺) 355.1480, found: 355.1479.



N-(*tert*-butyl)-5-{[4-(*tert*-butyl)-phenyl-sulfonyl]-quinolin}-8-amine (**3ad**):


General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol) and 4-(*tert*-butyl)-benzene-1-sulfonyl chloride **2d** (175 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **3ad** (74 mg, 75%) as a yellow solid. **M. p.**: 169-171 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.92 (d, *J* = 8.7 Hz, 1H), 8.65 (s, 1H), 8.31 (d, *J* = 8.6 Hz, 1H), 7.83 (d, *J* = 8.0 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 3H), 6.88 (d, *J* = 8.6 Hz, 1H), 1.55 (s, 9H), 1.27 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 156.2, 148.0, 146.5, 140.5, 137.8, 133.5, 133.3, 126.8, 126.1, 125.6, 123.1, 118.7, 104.0, 51.4, 35.2, 31.2, 29.1. **IR** (neat): 3357, 3347, 2963, 2929, 2869, 1564, 1383, 1299, 1218, 1193, 814, 673 cm⁻¹. **HR-MS** (ESI)

m/z calcd. for C₂₃H₂₉N₂O₂S ([M+H]⁺) 397.1950, found: 397.1949.




***N*-(*tert*-butyl)-5-[(4-(trifluoromethyl)phenyl)sulfonyl]quinolin-8-amine (3ae):**

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol), 4-(trifluoromethyl)benzene-1-sulfonyl chloride **2e** (183 mg, 0.75 mmol), and [RuCl₂(*p*-cymene)]₂ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **3ae** (52 mg, 51%) as a pale yellow solid. **M. p.**: 151-153 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.87 (d, *J* = 8.6 Hz, 1H), 8.67 (s, 1H), 8.33 (d, *J* = 8.7 Hz, 1H), 8.03 (d, *J* = 7.9 Hz, 2H), 7.69 (d, *J* = 7.9 Hz, 2H), 7.50 – 7.43 (m, 1H), 7.40 (s, 1H), 6.92 (d, *J* = 8.7 Hz, 1H), 1.56 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.8, 147.1, 146.9, 138.0, 134.1 (d, *J*_{C-F} = 33.1 Hz), 134.1, 132.7, 127.4, 126.3 (q, *J*_{C-F} = 3.7 Hz), 125.5, 123.4, 123.4 (d, *J*_{C-F} = 272.8 Hz), 116.6, 103.7, 51.4, 29.1. **¹⁹F-NMR** (377 MHz, CDCl₃) δ -63.1 (s). **IR** (neat): 3345, 2967, 2923, 1566, 1387, 1299, 1222, 841, 671 cm⁻¹. **HR-MS** (ESI) m/z calcd. for C₂₀H₂₀F₃N₂O₂S ([M+H]⁺) 409.1198, found: 409.1188.




***N*-(*tert*-butyl)-5-[(4-fluorophenyl)sulfonyl]quinolin-8-amine (3af):**

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol), 4-fluorobenzene-1-sulfonyl chloride **2f** (146 mg, 0.75 mmol), and [RuCl₂(*p*-cymene)]₂ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 15/1) yielded **3af** (47mg, 52%) as a pale yellow solid. **M. p.**: 139-141 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.82 (dd, *J* = 8.7, 1.3 Hz, 1H), 8.65 (dd, *J* = 4.1, 1.3 Hz, 1H), 8.30 (d, *J* = 8.7 Hz, 1H), 7.97 – 7.87 (m, 2H), 7.43 (dd, *J* = 8.7, 4.2 Hz, 1H), 7.29 (s, 1H), 7.10 (dd, *J* = 8.6, 8.6 Hz, 2H), 6.87 (d, *J* = 8.7 Hz, 1H), 1.55 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 164.9 (d, *J*_{C-F} = 254.5 Hz), 148.5, 146.8, 139.7 (d, *J*_{C-F} = 3.2 Hz), 138.0, 133.5, 132.8, 129.6, 129.5, 125.4, 123.2, 117.6, 116.4, 116.2, 103.6, 51.3, 29.1. **¹⁹F-NMR** (377 MHz, CDCl₃) δ -105.8 (s). **IR** (neat): 3353, 2974, 2929, 2869, 1566, 1383, 1220, 1146, 818, 687 cm⁻¹. **HR-MS** (ESI) m/z calcd. for C₁₉H₂₀FN₂O₂S ([M+H]⁺) 359.1230, found: 359.1225.




***N*-(*tert*-butyl)-5-[(4-chlorophenyl)sulfonyl]-quinolin-8-amine (**3ag**):**

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol), 4-chlorobenzene-1-sulfonyl chloride **2g** (158 mg, 0.75 mmol), and [RuCl₂(*p*-cymene)]₂ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 15/1) yielded **3ag** (42 mg, 45%) as a pale yellow solid. **M. p.**: 174-176 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.82 (d, *J* = 8.6 Hz, 1H), 8.66 (s, 1H), 8.30 (d, *J* = 8.5 Hz, 1H), 7.84 (d, *J* = 7.8 Hz, 2H), 7.42 (dd, *J* = 17.5, 8.2 Hz, 3H), 6.88 (d, *J* = 8.6 Hz, 1H), 1.55 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.5, 146.7, 142.1, 139.0, 137.9, 133.7, 133.1, 129.4, 128.4, 125.5, 123.3, 117.5, 103.8, 51.4, 29.2. **IR** (neat): 3363, 3083, 3059, 2965, 2923, 2853, 1564, 1381, 1309, 1216, 1197, 814, 671 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₉H₂₀ClN₂O₂S ([M+H]⁺) 375.0934, found: 375.0931.




***N*-(*tert*-butyl)-5-(naphthalen-2-ylsulfonyl)-quinolin-8-amine (**3ah**):**

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol) and naphthalene-2-sulfonyl chloride **2h** (170 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ah** (49 mg, 50%) as a pale yellow solid. **M. p.**: 183-185 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.94 (d, *J* = 8.6 Hz, 1H), 8.62 (s, 1H), 8.57 (s, 1H), 8.39 (d, *J* = 8.4 Hz, 1H), 7.96 (d, *J* = 7.1 Hz, 1H), 7.85-7.77 (m, *J* = 8.8 Hz, 3H), 7.58 (d, *J* = 5.0 Hz, 2H), 7.40 (d, *J* = 8.2 Hz, 1H), 6.91 (d, *J* = 8.5 Hz, 1H), 1.55 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.3, 146.6, 140.4, 137.9, 134.8, 133.6, 133.3, 132.3, 129.5, 129.4, 128.8, 128.0, 127.8, 127.5, 125.6, 123.2, 122.5, 118.1, 103.9, 51.4, 29.2. **IR** (neat): 3339, 2967, 2925, 2851, 1562, 1381, 1297, 1218, 1193, 814, 679 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₂₃H₂₃N₂O₂S ([M+H]⁺) 391.1480, found: 391.1475.




N-(*tert*-butyl)-5-(thiophen-2-ylsulfonyl)-quinolin-8-amine (**3ai**):

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol) and thiophene-2-sulfonyl chloride **2i** (137 mg, 0.75 mmol). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ai** (26 mg, 30%) as a yellow solid. **M. p.**: 163-165 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 9.03 (d, *J* = 8.5 Hz, 1H), 8.68 (s, 1H), 8.28 (d, *J* = 8.7 Hz, 1H), 7.63 (s, 1H), 7.50 (s, 2H), 6.99 (s, 1H), 6.86 (d, *J* = 8.4 Hz, 1H), 1.55 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.5, 146.8, 145.8, 138.0, 133.2, 132.1, 131.8, 127.4, 125.4, 123.2, 118.9, 103.6, 51.3, 29.2. **IR** (neat): 3349, 3094, 2967, 2925, 2853, 1566, 1383, 1313, 1220, 1195, 816, 683 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₇H₁₉N₂O₂S₂ ([M+H]⁺) 347.0888, found: 347.0880.



N-(*tert*-butyl)-5-(isobutylsulfonyl)-quinolin-8-amine (**3aj**):

General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol), 2-methylpropane-1-sulfonyl chloride **2j** (117 mg, 0.75 mmol), and [RuCl₂(*p*-cymene)]₂ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3aj** (44 mg, 55%) as a pale yellow solid. **M. p.**: 154-156 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.94 (d, *J* = 8.6 Hz, 1H), 8.73 (d, *J* = 3.9 Hz, 1H), 8.09 (d, *J* = 8.6 Hz, 1H), 7.53 (dd, *J* = 8.6, 4.1 Hz, 1H), 7.25 (s, 1H), 6.85 (d, *J* = 8.6 Hz, 1H), 3.05 (d, *J* = 6.3 Hz, 2H), 2.25 (dt, *J* = 13.5, 6.7 Hz, 1H), 1.56 (s, 9H), 1.03 (d, *J* = 6.7 Hz, 6H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.2, 146.8, 138.0, 133.5, 132.9, 125.8, 123.3, 117.8, 103.6, 64.7, 51.2, 29.2, 24.4, 23.0. **IR** (neat): 3396, 3332, 2961, 2874, 1566, 1534, 1389, 1295, 1126, 789 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₇H₂₅N₂O₂S ([M+H]⁺) 321.1637, found: 321.1635.




N-(*tert*-butyl)-5-(morpholin-4-ylsulfonyl)-quinolin-8-amine (**3ak**):


General procedure B was followed using *N*-(*tert*-butyl)quinolin-8-amine **1a** (50 mg, 0.25 mmol), morpholine-4-sulfonyl chloride **2k** (139 mg, 0.75 mmol), and [RuCl₂(*p*-cymene)]₂ (15.3 mg, 10.0 mol %). Purification by column chromatography on silica gel (PE/EA: 10/1) yielded **3ak** (35 mg, 40%) as a pale yellow solid. **M. p.**: 167-169 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.96 (dd, *J* = 8.7, 1.5 Hz, 1H), 8.71 (dd, *J* = 4.1, 1.5 Hz, 1H), 8.03 (d, *J* = 8.6 Hz, 1H), 7.49 (dd, *J* = 8.7, 4.1 Hz, 1H), 6.82 (d, *J* = 8.7 Hz, 1H), 3.69 (t, 4H), 3.09 (t, 4H), 1.56 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ 148.1, 146.8, 138.0, 134.4, 133.9, 126.0, 123.0, 113.3, 103.3, 76.8, 66.4, 51.2, 45.6, 29.2. **IR** (neat): 3357, 2971, 2923, 2855, 1568, 1526, 1220, 1150,

816, 720 cm^{-1} . **HR-MS** (ESI) m/z calcd. for $\text{C}_{17}\text{H}_{24}\text{N}_3\text{O}_3\text{S}$ ($[\text{M}+\text{H}]^+$) 350.1538, found: 350.1527.


Mechanistic Study



General procedure B was followed using **1a** (50 mg, 0.25 mmol), **2a** (143 mg, 0.75 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (7.7 mg, 5.0 mol %), K_2CO_3 (69 mg, 0.50 mmol), TEMPO (117 mg, 0.75 mmol), and 1.0 mL anhydrous DME. Purification by column chromatography on silica gel (PE/EA: 20/1) recovered 46 mg of **1a** (92%), no **3aa** was observed.




General procedure B was followed using **1a** (50 mg, 0.25 mmol), **2a** (143 mg, 0.75 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (7.7 mg, 5.0 mol %), K_2CO_3 (69 mg, 0.50 mmol), 1,1-Diphenylethylene (225 mg, 1.25 mmol), and 1.0 mL anhydrous DME. Purification by column chromatography on silica gel (PE/EA: 20/1) yielded **3aa** (12 mg, 14%) and **4** (125 mg, 50%) as a white solid. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.47 (d, $J = 8.3$ Hz, 2H), 7.36 (m, 2H), 7.35-7.28 (m, 4H), 7.20 (d, $J = 7.2$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 7.10 (d, $J = 7.0$ Hz, 2H), 6.99 (s, 1H), 2.38 (s, 3H). The spectra data are in accordance with those reported in the literature.^[3]



General procedure B was followed using *N*-(*tert*-butyl)-5-methoxyquinolin-8-amine **1o** (57 mg, 0.25 mmol), **2a** (143 mg, 0.75 mmol), $[\text{RuCl}_2(p\text{-cymene})]_2$ (7.7 mg, 5.0 mol %), K_2CO_3 (69 mg, 0.50 mmol), and 1.0 mL anhydrous DME. Purification by column chromatography on silica gel (PE/EA: 5/1) recovered 51 mg of **1o** (88%), no addition product of **1o** and **2a** was observed.

Synthesis of Complex 5







Procedure: In a microwave reaction vial equipped with a magnetic stir bar was added 0.4 mmol of **3aa** (dissolved in 2 mL EtOH), followed by 2 mL of 0.2 M HCl. The vial was capped and sealed, then heated in the microwave synthesis apparatus for 30 minutes at 180 °C. After basic aqueous workup (with 2 mL of 3 M NaOH, 1 mL of brine and 2 mL of EA), the organic layers were concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (PE/EA: 3/1) to afford the product **5** (95 mg, 80%) as a pale yellow solid. **M. p.:** 152-154 °C. **¹H-NMR** (400 MHz, CDCl₃) δ 8.88 (dd, *J* = 8.7, 1.5 Hz, 1H), 8.71 (dd, *J* = 4.1, 1.5 Hz, 1H), 8.31 (d, *J* = 8.3 Hz, 1H), 7.78 (d, *J* = 8.3 Hz, 2H), 7.46 – 7.40 (m, 1H), 7.22 (d, *J* = 8.1 Hz, 2H), 6.88 (d, *J* = 8.3 Hz, 1H), 5.66 (s, 2H), 2.34 (s, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ 149.9, 147.7, 143.5, 140.3, 137.5, 132.9, 132.9, 129.8, 127.0, 125.5, 123.3, 121.7, 106.6, 21.6. **IR** (neat): 3436, 3328, 2923, 1617, 1509, 1370, 1281, 1130, 814, 687 cm⁻¹. **HR-MS** (ESI) *m/z* calcd. for C₁₆H₁₅N₂O₂S ([M+H]⁺) 299.0854, found: 299.0859. The spectra data are in accordance with those reported in the literature.^[2]



References



- [1] N. Muresan, C. C. Lu, M. Ghosh, J. C. Peters, M. Abe, L. M. Henling, T. Weyhermüller, E. Bill and K. Wieghardt, *Inorg. Chem.*, 2008, **47**, 4579.
- [2] H.-W. Liang, K. Jiang, W. Ding, Y. Yuan, L. Shuai, Y.-C. Chen and Y. Wei, *Chem. Commun.*, 2015, **51**, 16928.
- [3] S. Mao, Y.-R. Gao, X.-Q. Zhu, D.-D. Guo and Y.-Q. Wang, *Org. Lett.*, 2015, **17**, 1692.


NMR Spectra













1f

¹⁹F-NMR
(377 MHz, CDCl₃)

63.01




8.61
8.61
8.60
8.60
7.96
7.94
7.93
7.36
7.35
7.34
7.26
6.64
6.63
6.62
6.61
6.60
6.59
6.57
6.57







1g



¹H-NMR
(400 MHz, CDCl₃)


1.53


















3aa



NOESY



























































3ae
¹⁹F-NMR
 (377 MHz, CDCl₃)






8.83
8.83
8.81
8.81
8.66
8.66
8.65
8.65
8.31
8.29
7.92
7.91
7.43
7.42
7.41
7.29
7.26
7.12
7.10
7.08
6.88
6.86







3af
¹H-NMR
 (400 MHz, CDCl₃)











3af
¹⁹F-NMR
 (377 MHz, CDCl₃)



















4

¹H-NMR
(400 MHz, CDCl₃)



5

¹H-NMR
(400 MHz, CDCl₃)




149.93
147.69
143.49
140.25
137.48
132.92
132.91
129.79
126.98
125.52
123.31
121.66

106.63

77.48
77.16
76.84

21.59



¹³C-NMR
(101 MHz, CDCl₃)

